Table 1.
Baseline Characteristics
| Adults | Children | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| rVSVΔG-ZEBOV-GP | Placebo | Total | rVSVΔG-ZEBOV-GP | Placebo | Total | |||||
| 1-dose | 2-dose | Pooleda | 1-dose | 2-dose | Pooleda | |||||
| Participants in population | 395 | 197 | 592 | 191 | 783 | 407 | 202 | 609 | 210 | 819 |
| Sex | ||||||||||
| Male | 213 (53.9%) | 110 (55.8%) | 323 (54.6%) | 110 (57.6%) | 433 (55.3%) | 222 (54.5%) | 117 (57.9%) | 339 (55.7%) | 115 (54.8%) | 454 (55.4%) |
| Female | 182 (46.1%) | 87 (44.2%) | 269 (45.4%) | 81 (42.4%) | 350 (44.7%) | 185 (45.5%) | 85 (42.1%) | 270 (44.3%) | 95 (45.2%) | 365 (44.6%) |
| Age, years | ||||||||||
| Mean | 31.1 | 29.7 | 30.6 | 30.7 | 30.6 | 8.6 | 8.2 | 8.4 | 8.3 | 8.4 |
| SD | 13 | 11.8 | 12.6 | 13 | 12.7 | 4.9 | 5.1 | 5 | 5 | 5 |
| Median | 27 | 26 | 26.5 | 26 | 26 | 9 | 8 | 9 | 8 | 9 |
| Range | 18–74 | 18–72 | 18–74 | 18–76 | 18–76 | 1–17 | 1–17 | 1–17 | 1–17 | 1–17 |
| HIV statusb | ||||||||||
| Negative | 382 (96.7%) | 195 (99.0%) | 577 (97.5%) | 188 (98.4%) | 765 (97.7%) | 407 (100.0%) | 202 (100.0%) | 609 (100.0%) | 210 (100.0%) | 819 (100.0%) |
| Positive | 13 (3.3%) | 2 (1.0%) | 15 (2.5%) | 3 (1.6%) | 18 (2.3%) | 0 | 0 | 0 | 0 | 0 |
Abbreviations: HIV, human immunodeficiency virus; SD, standard deviation.
aPooled = rVSVΔG-ZEBOV-GP 1-dose or 2-dose group.
bHIV-positive status was an exclusion criterion for participants <18 y of age.